• Novel Prognostic Classification of AML

  • Minimal Residual Disease

  • Bioinformatics

  • Genomics-related Ethical, Economic and Legal Support

The Leucegene project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies

Researchers

The Leucegene team utilises Next-Generation sequencing, chemogenomic and precision medicine approaches to develop innovative tools, treatments and collaborations to cure AML.

Health Care Providers

We have developed a new prognostic test and look to drive implementation through socio-economic studies and clinician engagement.

Patients

Our Leucegene approach will refine precision medicine in AML and provide cures for this disease.

Latest News

Recent publication of the Leucegene team in Blood Cancer Journal

Bacelli et al. published A novel approach for the identification…

Recent publication of the Leucegene team in Blood Cancer Journal

/
Maiga et al. published Transcriptome analysis of G protein-coupled…

An additional publication of the Leucegene team in Blood

Lavallée et al. published Chemo-genomic interrogation of CEBPA…

Upcoming Events

Our Partners